On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.’s (NASDAQ:PGEN) Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).
RRP is a rare chronic disease caused by the human papillomavirus (HPV) and wart-like tumors grow on and around the vocal cords.
